Evidence map›Paper›PMID 42908892›Full record

ReviewOne health (Amsterdam, Netherlands)2026

Extended spectrum beta lactamases and carbapenemase-producing

Magreth Erick Macha, Alisen Ayitewala, Damalie Nakanjako

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in One health (Amsterdam, Netherlands), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Magreth Erick MachaSt. Francis University College of Health and Allied Sciences, Ifakara, Tanzania.
Alisen AyitewalaCentral Public Health Laboratories (CPHL), National Health Laboratory and Diagnostic Services (NHLDS), Ministry of Health, Kampala, Uganda.
Damalie NakanjakoDepartment of Medicine, School of Medicine, Makerere University College of Health Sciences, Kampala, Uganda.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Antimicrobial resistance (AMR) is escalating in East Africa through close human-animal-environment interactions. Extended-spectrum beta-lactamases (ESBL) and carbapenemase-producing Methods: Following PRISMA-ScR guidelines, PubMed and Scopus were searched, identifying 279 records published between 2015 and 2025. After removing duplicates and screening, 185 articles were assessed for eligibility; 154 studies spanning human, animal and environmental sources met the inclusion criteria. Two reviewers independently extracted epidemiological, microbiological and molecular data in Covidence, including resistance genes and transmission evidence. Results: The 154 included studies spanned 11 East African countries, led by Ethiopia ( Conclusion: This review maps the current evidence on landscape for ESBL/carbapenemase- producing

Indexed as

AnimalCarbapenemaseEast AfricaEnvironmentESBLEscherichia coliGenomicsHumanOne healthSurveillance

Identifiers

PMID42908892
PMCPMC13683449

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.